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ABSTRACT
Tuberculosis is still a major health problem worldwide and one of the main causes of
death by a single infectious agent. Only few drugs are really effective to treat
tuberculosis, hence, the emergence of multiple, extensively, and totally drug resistant
bacilli compromises the already difficult antituberculosis treatments. Given
the persistent global burden of tuberculosis, it is crucial to understand the underlying
mechanisms required for the pathogenicity of Mycobacterium tuberculosis (Mtb), the
causal agent of tuberculosis, in order to pave the way for developing better drugs and
strategies to treat and prevent tuberculosis.  
The exclusive mycobacterial cell wall lipids such as trehalose monomycolate and
dimycolate (TMM, TDM), phthiocerol dimycocerosate (PDIM), sulpholipid-1 (SL-1),
diacyl trehalose (DAT), and pentacyl trehalose (PAT), among others, are known to
play an important role in pathogenesis; thus, proteins responsible for their transport
are potential virulence factors. MmpL and MmpS proteins mediate transport of
important cell wall lipids across the mycobacterial membrane. In Mtb, MmpL3,
MmpL7 and MmpL8 transport TMM, PDIM and SL-1 respectively. The
translocation of DAT and biosynthesis of PAT is likely due to MmpL10.  MmpL and 
MmpS proteins are involved in other processes such as drug efflux
(MmpL5 and MmpL7), siderophore export (MmpL4/MmpS4 and MmpL5/MmpS5),
and heme uptake (MmpL3 and MmpL11). Altogether, these proteins can be regarded
as new potential targets for antituberculosis drug development. We will review recent
advances in developing inhibitors of MmpL proteins, in the challenging context of 
targeting membrane proteins and the future prospects for potential antituberculosis
drug candidates.
Keywords
tuberculosis, lipid transport, MmpL/S proteins, drug resistance, transport proteins
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Tuberculosis along history
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis, has been 
present in the human population since antiquity. Initially, it was thought that during 
the domestication of animals in the Neolithic period, Mycobacterium bovis strains 
from infected cattle evolved and acquired the capability of infecting humans, hence 
originating human tuberculosis [1]. However, it is now widely accepted that the 
ancients Mtb strains were originated from environmental mycobacteria 70 000 years 
ago in Africa [2, 3]. The introduction of agriculture, civilization and the increase in 
human population density led to the selection of virulent and transmissible Mtb 
strains. These modern Mtb strains spread throughout the world causing the 
tuberculosis epidemics that ravaged mankind for centuries [4].
Nowadays, 9 million people fell ill with tuberculosis and 1.5 million died in 2013 
(including 360 000 deaths among HIV-positive people) according to the most recent 
report of the World Health Organization (WHO) [5]. At present, tuberculosis is the 
second leading cause of death from an infectious agent worldwide, after the Human 
Immunodeficiency Virus (HIV), in spite of the fact that we have powerful tools in order 
to face tuberculosis: vaccination, diagnostics and treatments.
Tuberculosis treatment and drug resistance
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Drug treatment is the only effective therapy for tuberculosis. Drugs are classified into 
three groups (Table 1) based on evidence of efficacy, potency and experience of use 
[6].
 First-line antituberculosis drugs are the most effective and widely used drugs 
for the treatment of drug-susceptible tuberculosis.
 Second-line antituberculosis drugs are reserved for treating bacilli resistant to 
first-line therapy. A drug may be classed as second-line instead of first-line for 
being less effective than the first-line drugs (e.g. para-aminosalicylic acid), 
having toxic side-effects (e.g. cycloserine) or being effective, but unavailable 
in many developing countries (e.g. fluoroquinolones).
 Third-line antituberculosis drugs are characterized for being less effective (e.g. 
clarithromycin) or because their efficacy has not been fully proven (e.g. 
clofazimine).
With appropriate antibiotic treatment, around 90% of HIV-negative patients with drug-
susceptible tuberculosis can be cured in 6 months using a combination of rifampicin 
(Rif), isoniazid (Inh), pyrazinamide (Pza) and ethambutol (Emb) for 2 months, 
followed by a four-month continuation phase of Rif and Inh [5]. The main reason for 
prescribing this combination of medicines in the treatment of tuberculosis is because 
the likelihood of the emergence of multiple drug resistance bacteria is virtually 
impossible [7], apart from the fact that the distinct antituberculosis drugs have 
different modes of action: Inh are bactericidal against replicating bacteria; Emb is 
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bacteriostatic at low doses, but is used in tuberculosis treatment at higher, 
bactericidal doses; Rif is bactericidal and has a sterilizing effect; and Pza is only 
weakly bactericidal, but is very effective against bacteria located in acidic 
environments, inside macrophages, or in areas of acute inflammation, where they 
enter into a non-replicative condition. Thus, the combination of all these drugs targets 
all subpopulations of Mtb, i.e. those actively replicating and those in a non-replicative 
state.
Monotherapy, irregular drug supply, poor drug quality, inappropriate prescription, 
poor adherence to treatment and unsuitable supervision and support on the part of 
health personnel, can contribute to appearance and selection of drug-resistant Mtb
strains that can disseminate and cause drug resistant tuberculosis. Depending on the 
drug resistance pattern, three major categories have been defined:
 Multidrug-resistant (MDR) strains are those resistant to Inh and Rif. In 2013, 
the highest levels of MDR tuberculosis were found in Eastern Europe and 
central Asia, where in some countries more than 20% of new tuberculosis
cases and more than 50% of those previously treated for tuberculosis have 
MDR tuberculosis [5]. 
 Extensively drug-resistant (XDR) strains are MDR strains (i.e, resistant to Inh 
and Rif) that are also resistant to a quinolone and one of the second-line 
injectable drugs (kanamycin, amikacin or capreomycin). In 2006, the first XDR 
tuberculosis outbreak was described in KwaZulu-Natal in South Africa. The 
mortality rate among HIV-positive patients, with limited or no access to highly 
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active antiretroviral therapy was 98%, after a median survival period from 
diagnosis of only 16 days [8].
 Totally drug-resistant (TDR) refers to strains that are resistant to all available 
tuberculosis drugs, although the number and level of resistance to each drug 
has not yet been precisely defined. To date, only a limited number of TDR
tuberculosis cases have been confirmed in Iran, India, South Africa and Italy 
[9].
All these are cases of acquired resistance [7]. The mechanisms by which bacteria in 
general acquired drug resistance are: barrier mechanisms (decreased 
permeability/increased efflux), degrading/inactivating enzymes, modification of 
pathways involved in drug activation/metabolism, and drug target modification 
(mutations) or target amplification [10]. Mtb in particular is able to acquire drug 
resistance by spontaneous mutations in chromosomal genes then leading to target 
modification, target amplification, reduced ability for activating drugs, or increased 
capacity for inactivating drugs (Table 2); no horizontal transfer of resistance genes 
had been reported [11].
Mycobacterial cell envelope: biochemically complex, pharmacologically 
interesting
The mycobacterial envelope is unique, both in molecular composition and in the 
architectural arrangement of its constituents (Fig. 1; adapted from [12, 13]). Its 
complex structure is composed of a typical phospholipid bilayer plasma membrane, 
an outer membrane called mycomembrane, and an outermost layer known as the 
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capsule. The plasma membrane is composed mainly of anionic phospholipids in a 
bilayer arrangement with proteins. The mycomembrane consists of an asymmetric 
lipid bilayer made of long chain (C60-C90) mycolic fatty acids in the inner leaflet, and 
free intercalating glycolipids and waxy components on the outer leaflet. Cryo-electron 
microscopy images support a folded or compact configuration of these mycolic 
chains, which reminiscent of Gram-negative bacterial cell walls [14-16], and also 
confirm that the measured thickness of the outer membrane is consistent with the 
size of mycobacterial porins, such as MspA from M. smegmatis, which may therefore 
form channels in this bilayer [14]. The outer and inner membrane form a periplasmic 
space, with the presence of a thin layer of peptidoglycan covalently linked to 
arabinogalactan and lipoarabinomannan, which in turn are bound to mycolic acids. 
Peptidoglycan, arabinogalactan and mycolic acids form the cell wall skeleton. The 
capsule is mainly composed of polysaccharides, proteins and small amounts of 
lipids, and it is considered to have a different molecular composition in pathogenic 
and non-pathogenic species [17]. The outermost layer is visible in conventional 
electron microscopy preparations only when cultures have been grown in free 
detergent medium. It is thought that mycobacterial growth under laboratory routine 
culturing conditions (with a detergent as Tween-80) promotes removing of this layer 
[13].
The mycobacterial envelope is involved in important roles, such as defining the 
shape of the cell and providing mechanical and osmotic protection. Its unusual high 
hydrophobicity makes it an efficient barrier for chemotherapeutic agents. Other 
important function is the transport of molecules, including nutrients, ions and toxic 
metabolites. During infection, cell-wall compounds have been shown to trigger a set 
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of biological effects including adjuvanticity, toxicity, immune down-modulation, and 
arrest of phagosome maturation [18]. For these reasons, antitubercular drugs acting
by inhibiting biosynthesis or assembly of mycobacterial cell envelope components
are very effective antituberculosis drugs. This is the case of Inh, one of the two major 
drugs in tuberculosis treatment, and ethionamide: both are prodrugs that need 
activation by catalase-peroxidase (KatG) and mono-oxygenase (EthA), and their 
active products inhibit InhA, and enzyme involved in mycolic acids biosynthesis; 
similarly, Emb directly blocks biosynthesis of arabinan and its assembly into the 
bacterial arabinogalactan. Since these three drugs (Inh, ethionamide, and Emb) 
inhibit biosynthesis of cell wall components that are exclusive of mycobacteria and a 
few related genera, these drugs are extremely specific for mycobacterial pathogens, 
having little (if any) activity against other bacterial pathogens.
In addition to mycolic acids, there are many other lipids that are also very important 
components of the mycobacterial cell wall, most of them being exclusive for 
mycobacteria. Among them can be found trehalose dimycolate (TDM), often referred 
as cord factor, trehalose monomycolate (TMM), glucose monomycolate (GMM), 
glycerol monomycolate, diacyl trehaloses (DAT), triacyl trehaloses (TAT), pentacyl
trehaloses (PAT), the recently characterized family of mannosyl--1-
phosphomycoketides, sulpholipids (SLs), phenolic glycolipids (PGLs) and phthiocerol 
dimycocerosate (PDIM). Other major glycolipids are lipomannan (LM), 
lipoarabinomannan (LAM) and phosphatidylinositol mannosides (PIMs). The 
importance of lipids for mycobacteria must be regarded from a double point of view: 
on the one hand, they contribute to the structure of the mycobacterial cell envelope, 
and in addition, many lipids have important roles in pathogenesis. A well-known 
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example of this is PDIM, which is found only in pathogenic mycobacteria; PDIM is 
essential during the early step of infection when bacilli encounter their host 
macrophages. In fact, mutant Mtb strains defective in genes encoding enzymes that 
take part in biosynthesis of PDIM (such as FadD26, FadD28 enzymes in cooperation 
with polyketide synthases) or in PDIM transport (such as DrrC protein, which forms 
an ABC transporter along with DrrB and DrrC) showed attenuated phenotypes in 
mice [19, 20]. Similarly, PIMs and mannose-capped lipoarabinomannan (Man-LAM) 
both interfere with phagosome maturation [21].
In summary, proper localization of lipids in the mycobacterial cell wall, mostly in the 
outermost layer, is needed for their role in pathogenicity, thus making transport of 
lipids an essential process in mycobacterial cells. Proteins transporting lipids are 
therefore important virulence factors and attractive drug targets.
Proteins for lipid transport in M. tuberculosis
Efflux pumps are membrane roteins that transport actively a wide variety of 
compounds across bacterial envelope. They have been classified into five 
superfamilies: ATP-binding cassette (ABC), major facilitator super-family (MFS), 
resistance nodulation division (RND), small multidrug resistance (SMR) and 
multidrug and toxic-compound extrusion (MATE). While MFS, SMR, RND and MATE 
members are secondary transporters, typically energized by the proton motive force 
(H+ or Na+), members of the ABC superfamily use ATP as the energy source and are 
considered as primary transporters [22]. Whereas efflux pumps are mostly known 
because of the transport of drugs from the cytoplasm, other efflux pump substrates 
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are sugars, lipids, proteins, synthetic compounds, toxic metabolites, host-defence 
molecules, virulence factors, etc. Such a heterogeneous substrate profile allows 
bacterial efflux pumps to play diverse roles in drug resistance, virulence, bacterial cell 
physiology, and detoxification [22], among others.
Mce proteins are ABC transporters implicated in virulence. The Mce proteins are 
encoded by the mce1, mce2, mce3 and mce4 operons in the genome of Mtb. The 
involvement of Mce4 transport system in cholesterol import and intracellular survival 
has been confirmed [23, 24], but the role of mce1, mce2 and mce3 operons is not 
clearly established, especially in the case of the mce3 operon. As regards to mce1
operon, it has been suggested that these proteins may serve as a mycolic acid re-
importer [25], and mce2 operon might be related in sulpholipid transport [26]. Due to 
their most probable implication in lipid metabolism, the Mce proteins may modulate 
pathogenicity through changes in Mtb lipid pathways.
A special case for lipid transport: the MmpL and MmpS families of proteins
The transport of lipids in Mtb is predominantly via a family of proteins termed MmpL 
proteins (Mycobacterial Membrane Protein Large) belonging to the RND family of 
membrane proteins. The Mtb genome possesses 15 different genes encoding for 
RND proteins [27], 13 of which belong to MmpL (Table 3) protein family. Mutants with 
disruptions in mmpL2, mmpL4, mmpL5, mmpL7, mmpL8, mmpL10, and mmpL11
showed significant attenuation for growth in mice lungs [20, 28-30]. Notably, the first 
Mtb genome also revealed that many clusters harbouring polyketide synthase genes
with a known or putative role in lipid biosynthesis also contained an mmpL gene 
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suggesting that the function of the mmpL gene was associated with the cognate lipid 
species produced by the enzymes encoded by the cluster. The first role for MmpLs in 
lipid transport was demonstrated by Cox et al [31] who isolated an mmpL7 mutant 
from a signature-tag mutagenesis screen. The mutant was found to be defective in 
PDIM transport and found to accumulate the complex lipid intracellularly [31]. mmpL7
is present in the same cluster that encodes enzymes responsible for the biosynthesis 
of the pthiocerol (ppsA-E) and mycocerosic acid (mas) moieties of PDIM. 
Subsequently, another MmpL protein, MmpL8 was shown to be involved in the 
transport of SLs [29, 32]. Interestingly, while no sulpholipid-1 (SL-1) was detected in 
the cell envelope of Mtb, the mmpL8 mutant accumulated an intermediate of SL-1, 
termed SL-1278, indicating that some, if not all MmpLs were involved in transporting 
intermediates, which were consequently processed further outside the cell [29, 32].
More recently, the functions of other mmpL genes have been deciphered. 
MmpL10 was shown to be involved in the translocation of acylated trehaloses; loss of 
mmpL10 function led to intracellular accumulation of DATs [33]. Additionally, PATs
were missing from the cell surface, indicating that the translocation of DATs by 
MmpL10 was likely requir d for the subsequent acylation of DAT substrates to yield 
extracellular PATs. MmpL proteins are also involved in the transport of mycolic acid 
derived lipids. mmpL3, the only essential mmpL gene in Mtb was shown to be 
involved in the transport of TMM [34, 35] using a conditional mutant of the mmpL3
homologue of Mycobacterium smegmatis. Furthermore, mmpL11, located in the 
same cluster as mmpL3 was shown to be involved in the export of monomeromycolyl 
diacylglycerol (MMDAG) [36].
Page 13 of 39
Ac
ce
pte
d M
an
us
cri
pt
13
There is also a growing line of evidence that suggests the MmpLs are not just
transporters, but may be involved in the formation of membrane-associated scaffolds 
that facilitate the coupling of lipid biosynthesis with transport. Four mmpL containing 
clusters in Mtb also contain a gene encoding an MmpS protein (Mycobacterial 
Membrane Protein Small). In M. smegmatis, MmpS4 was shown to be required for 
biosynthesis and export of a surface exposed glycopeptidolipid [37]. A domain of 
MmpL7 was shown to interact PpsE, an enzyme involved in PDIM biosynthesis [38].
MmpL3 was also shown to co-localise with meromycolate producing FAS-II complex 
components at the septa and poles of the mycobacterial cell [39].
Other roles for MmpL and MmpS proteins in M. tuberculosis
Besides lipid transport, MmpL and MmpS proteins are involved in other bacterial 
processes, including drug resistance and siderophore export [40] (MmpL4/MmpS4 
and MmpL5/MmpS5), and heme uptake [41, 42] (MmpL3 and MmpL11); the 
acquisition of iron is an essential attribute of pathogenic bacteria so as to establish a 
successful infection.
a) Drug resistance
Early studies suggested that MmpL proteins did not play a significant role in intrinsic 
resistance to drugs in Mtb [30]; although this seems to be the general case, a few 
examples have been reported recently involving MmpL proteins in resistance to 
certain drugs. The MmpL5-MmpS5 proteins were originally characterised for their 
contribution to drug resistance in Mtb, which was mediated by active efflux of 
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econazole and other substrates from cells [43]. In recent years, these proteins were 
linked to cross-resistance between clofazimine (a traditional drug to treat leprosy, 
which is also considered as a third-line drug for use against drug resistant
tuberculosis) and bedaquiline (a recently approved drug for treatment of MDR 
tuberculosis) [44, 45]. In all cases, drug resistance was mediated by increased 
transcription of these two genes, mediated by mutations in a regulatory protein 
encoded by Rv0678 gene; the latter could probably regulate as well expression of 
mmpL4-mmpS4 and mmpL2 –mmpS2 [46].
Evidences about a role for MmpL7 transporter in isoniazid resistance are still 
controversial: isoniazid readily increases transcription of mmpL7 gene in Mtb [47], 
although overexpression of mmpL7 gene only resulted in resistance to isoniazid in 
the heterologous host M. smegmatis [48].
The link between MmpL3 and drug resistance seems to be indirect and has not been 
fully characterised yet. MmpL3 interacts with Wag31 protein as a part of a large 
network of interactions between proteins involved in fatty acid metabolism; as a 
consequence of Wag31 knock-down, resistance to lipophilic drugs was altered [49]. 
b) Iron acquisition
Mtb has developed two strategies for acquiring iron when infecting the human host, 
and MmpL proteins play an important role in both pathways. First, a secreted protein, 
Rv0203, binds heme groups (an abundant iron source in mammalian tissues and 
proteins) in the outside of the bacteria, and then transfer it to MmpL3 and MmpL11 
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proteins that will transport iron-containing heme groups through the mycobacterial 
membrane into the cytoplasm, where MhuD protein will degrade heme group 
releasing its iron content [41]. Second strategy consists on producing and exporting 
siderophores (mycobactins and carboxymycobactins) that will bind non-heme iron
outside the bacterial cell. MmpS4 and MmpS5 proteins resulted essential for 
producing and releasing siderophores, hence indicating a role for MmpL4-MmpS4 
and MmpL5-MmpS5 protein complexes in exporting siderophores in Mtb [40]. Iron-
containing siderophores are subsequently uptaken by a pathway independent of 
MmpL4-MmpS4 and MmpL5-MmpS5, which complete the siderophore recycling 
system; in those mutants lacking MmpS4 and MmpS5 proteins, siderophores then 
accumulate in the cytoplasm resulting in lethality for the bacteria [50].
Inhibitors of MmpL proteins: new drugs for the future?
MmpL proteins have been investigated for their contribution to virulence, drug 
resistance, and other processes in Mtb for more than a decade, but it was just in the 
last three years when MmpL3 (that had been predicted to be the only essential 
protein of this family [30]) emerged as a drug target. From 2012, several families of 
structurally different chemical entities have been shown to inhibit MmpL3 (Table 4) 
opening a new field in the inhibition of mycolic acids transport [34, 51-62]. Notably, 
compound SQ109, which was identified a decade ago in a combinatorial chemistry-
based search for ethambutol analogues, currently on phase III of clinical trials, was 
revealed as an inhibitor of MmpL3 [54].
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Discovering a brand new drug target in Mtb along with 7 new families of potential 
inhibitory compounds in such a short period of time seemed like a success in 
antituberculosis drug discovery never before seen. Further investigation into their
mechanism of action demonstrated that most of these compounds are also targeting 
several enzymes in the menaquinone biosynthesis pathway and electron transport 
chain; as a consequence, respiration and ATP synthesis were inhibited and the 
transmembrane electrochemical proton gradient (the energy source in many 
transport processes) were abolished [63, 64]. Then, since multiple protein targets can 
be affected simultaneously, the probability of selection of resistant mutants remains 
very low for most of these compounds. Also, given that the electrochemical gradient, 
a general process in many cells, is targeted, compounds in this group such as 
SQ109, BM212 [55, 58] and the THPPs [60] have shown to be active against other 
bacterial and fungal pathogens lacking mycolic acids and MmpL3-related targets. In 
any case, the activity of these compounds against drug resistant and MDR isolates of 
Mtb and their synergy with current antituberculosis therapy (notably in the case of 
SQ109) makes conceivable the possibility to shorten current antituberculosis 
treatment, one of the key points that will be essential in the near future to control this 
terrible disease.
Future directions: the impact of MmpL proteins & lipid transport in 
antituberculosis drug discovery
For decades, the role of transport proteins in drug resistance in Mtb was considered 
to be marginal. While most of resistant strains, isolated from clinical specimens or 
selected under laboratory conditions, carried mutations in genes encoding target 
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proteins or activating enzymes, concerning efflux pumps the situation was far distant 
to that in Gram-negative bacteria, where efflux-mediated drug resistance is 
prominent in many pathogens [65].
Being enthusiastic about the role of transport proteins in drug resistance, we 
suggested that efflux pumps could have a role in transporting new drugs in 
development, and hence they should be taken into account in antituberculosis drug 
discovery programmes [66]. Recently, several publications have confirmed this
hypothesis, and transport proteins were genetically related with resistance to 
peptidoglycan synthesis inhibitors [67] and several other families of new compounds 
with antituberculosis activity [68, 69]. Notably, among a series of spectinomycin 
derivatives, the most active molecules were those that escaped transport by the 
Rv1258c efflux pump [70]. Similarly, this has been the case for the MmpL5 protein 
since it has been demonstrated to transport bedaquiline [44, 45]. Altogether, it 
becomes clear that efflux transporters must be taken into consideration in any 
tuberculosis drug discovery programs in order to estimate the likelihood of the new 
molecules for being transported out of bacterial cells.
One of the most successful approaches in antimicrobial therapy has been the 
combination of beta-lactam antibiotics with inhibitors of beta-lactamases, and this has 
inspired a similar strategy for drug transport proteins [66, 71]. For years, this 
approached seemed unrealistic, given the toxicity of most efflux inhibitors, which 
remained useful only under laboratory conditions to demonstrate efflux mechanism. 
However, discovery of several MmpL3 inhibitors on recent years has brought the 
attention back to this field. Being a transport protein of the RND superfamily, MmpL3 
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is however rather distinct from conventional efflux pumps of the same family such as 
AcrAB-TolC from E. coli, in terms of substrate specificity and transport activity: 
whereas AcrAB-TolC has a clear role in detoxification by transporting out antibiotics 
and other noxious products, MmpL3 has a major role as both a trehalose 
monomycolate (TMM) transporter (hence contributing to the assembly of 
mycobacterial cell envelope) and a heme importer [34, 35, 42]. It is tempting to 
believe that inhibiting a protein involved in two such different and important pathways 
is like having found the Achilles’ heel of Mtb. In addition, since several of these 
MmpL3 inhibitors act by dissipating the proton gradient, which is the energy source 
used by MmpL3 itself and many other transport proteins [63, 64], it is expected that 
lipid transport in general (not only TMM transport) would be greatly affected, given 
the implication of other MmpL proteins in the transport of other essential lipids (PDIM 
in the case of MmpL7, sulpholipid-1 in the case of MmpL8, acylated trehaloses in the 
case of MmpL10, and monomeromycolyl diacylglycerol in the case of MmpL11).
In summary, MmpL proteins have emerged also as attractive drug targets in Mtb,
given their pivotal role in lipid transport (and other essential processes) in this 
pathogen. Including specifically MmpL proteins in drug discovery programmes could 
be challenging, given the intrinsic difficulty to work with membrane proteins, but this 
should be overcome by the expectations of finding a new effective drug candidate 
against tuberculosis.
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Table 1. Drugs used in the treatment of tuberculosis.
Groups of drugs Drugs
First-line drugs Isoniazid
Rifampicin
Pyrazinamide
Ethambutol
Rifapentine
Rifabutin
Second-line drugs Aminoglycosides (Streptomycin, Kanamycin, 
Amikacin)
Polypeptides (Capreomycin, Viomycin)
Fluoroquinolones (Ciprofloxacin, Levofloxacin, 
Moxifloxacin, Ofloxacin, Gatifloxacin)
Para-aminosalicylic acid
Cycloserine
Terizidone
Ethionamide
Prothionamide
Thioacetazone
Linezolid
Third-line drugs Clofazimine
Linezolid
Amoxicillin plus clavulanate
Imipenem plus cilastatin
Clarithromycin
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Table 2. The commonly used antituberculosis drugs with the genes associated 
with their respective resistance and major mechanism.
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major mechanismajor mecha nism.
Drug or 
drug class
Mechanis
m of action
Genes 
associated 
with drug 
resistance
Gene 
number*
Protein 
function
Mechanis
m of drug 
resistance
Rifamycins 
(rifampicin, 
rifabutin, 
etc.)
Inhibition of 
RNA 
synthesis
rpoB Rv0667
RNA 
polymerase 
ß-subunit
Target 
modificatio
n
Isoniazid
Inhibition of 
mycolic 
acid 
biosynthesi
s and 
multiple 
effects in 
DNA, lipids, 
carbohydrat
es, and 
NAD 
metabolism
katG Rv1908c
Catalase-
peroxidase 
enzyme
Decreased 
drug 
activation
inhA Rv1484
NADH-
dependent 
enoyl-acyl 
carrier 
protein
Target 
amplificatio
n or 
modificatio
n
Depletion 
of 
membrane 
energy
and other 
effects
Inhibition of 
arabinogala
ctan
synthesis
Streptomyci
n
Inhibition of 
protein 
synthesis
rpsL Rv0682
12S 
ribosomal 
protein
Target 
modificatio
n
rrs 
MTB00001
9
16S rRNA
Target 
modificatio
n
gidB Rv3919c
7-
Methylguan
osine 
methyltrans
ferase
Target 
modificatio
n
Kanamycin/ 
amikacin
Inhibition of 
protein 
synthesis
rrs 
MTB00001
9
16S rRNA 
Target 
modificatio
n
eis Rv2416c
Aminoglyco
side 
acetyltransf
erase 
Increased 
drug 
inactivation
Capreomyci
n
Inhibition of 
protein 
synthesis
rrs 
MTB00001
9
16S rRNA 
Target 
modificatio
n
tlyA Rv1694
rRNA 
methyltrans
ferase 
Target 
modificatio
n
Quinolones
Inhibition of 
DNA 
gyrase
gyrA Rv0006
DNA 
gyrase A
Target 
modificatio
n
gyrB Rv0005
DNA 
gyrase B
Target 
modificatio
n
Pyrazinami
de
pncA Rv2043c
Pyrazinami
dase
Decreased 
drug 
activation
Ethambutol embCAB Rv3793-5
Arabinosyltr
ansferases
Target 
modificatio
n
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Ethionamid
e
Inhibition of 
mycolic 
acid 
synthesis
ethA Rv3854c
Mono-
oxygenase
Decreased 
drug 
activation
ethR Rv3855
Transcriptio
nal 
regulatory 
repressor 
protein 
(TetR 
family)
Decreased 
drug 
activation
inhA Rv1484
NADH-
dependent 
enoyl-acyl 
carrier 
protein
Target 
amplificatio
n and 
modificatio
n
Inhibition of 
folic acid 
and iron
metabolism
ribD Rv2671
Enzyme in 
riboflavin 
biosynthesi
s
Cycloserine
Peptidoglyc
an 
biosynthesi
s
alr Rv3423c
Alanine 
racemase
ddl Rv2981c
D-Alanine-
D-alanine 
ligase
cycA Rv1704c
Bacterial D-
serine/L- 
and D-
alanine/glyc
ine/D-
cycloserine 
proton 
symporter
Bedaquiline
Inhibition of 
ATP 
synthesis
atpE Rv1305
ATP 
synthase
Target 
modificatio
n
Linezolid
Inhibition of 
protein 
synthesis
rrl 
MTB00002
0
23S rRNA
Target 
modificatio
n
rplC Rv0701
50S 
ribosomal 
protein L3
Target 
modificatio
n
*: Gene numbers are given according to Tuberculist database (http://tuberculist.epfl.ch/)
Para-
aminosalicy
lic acid
thyA Rv2764c
Thymidylat
e synthase
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Table 3: MmpL and MmpS proteins of Mycobacterium tuberculosis H37Rv
Name Rv number
Protein length
(amino acids)
MmpL1 Rv0402c 958
MmpL2 Rv0507 968
MmpL3 Rv0206c 944
MmpL4 Rv0450c 967
MmpL5 Rv0676c 964
MmpL6 Rv1557 397
MmpL7 Rv2942 920
MmpL8 Rv3823c 1089
MmpL9 Rv2339 962
MmpL10 Rv1183 1002
MmpL11 Rv0202c 966
MmpL12 Rv1522c 1146
MmpL13a Rv1145 303
MmpL13b Rv1146 470
MmpS1 Rv0403c 142
MmpS2 Rv0506 147
MmpS3 Rv2198c 299
MmpS4 Rv0451c 140
MmpS5 Rv0677c 142
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Table 4: Inhibitors of MmpL3
Drug Structure References
SQ109 [54]
1,5-diarylpyrrole 
derivatives
(BM212)
[55, 58]
adamantyl ureas
(AU1235)
[34, 57, 61]
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benzimidazole (C215) [62]
tetrahydropyrazolo[1,5-
a]pyrimidine-3-
carboxamides (THPPs) 
[60]
N-benzyl-6’,7’-
dihydrospiro[piperidine-
4,4’-thieno[3,2-
c]pyrans 
[60]
indolecarboxamides [56, 59]
